Pediatric Zollinger-Ellison Syndrome Medication
- Author: Tiffany J Patton, MD; Chief Editor: Carmen Cuffari, MD more...
Inhibition of gastric acid secretion with proton pump inhibitors (PPIs) is mandatory to prevent complications of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome (ZES). PPIs have proven to be safe, without side effects even after long-term use. The goal is to reduce basal acid output (BAO) to levels less than 10 mEq/h 1 hour before the next dose in patients without gastric acid–reducing surgery and less than 5 mEq/h in patients with previous acid-reducing gastric surgery.
Proton Pump Inhibitors
Proton pump inhibitors (PPIs) are used to reduce gastric acid hypersecretion. Dosing should be adequate to achieve a basal acid output (BAO) of less than 10 mEq/h. Dosing may vary in each patient. Children may require relatively higher doses per kilogram than adults.
Lansoprazole is a substituted benzimidazole that covalently and irreversibly binds the hydrogen potassium/ATPase, thereby inhibiting acid secretion. This agent is available as an intravenous (IV) formulation, oral (PO) caps, or solutabs. Strawberry-flavored solutabs can be dissolved in water for easy administration to children. Dissolve the 15-mg solutab in 4 mL of water and the 30-mg solutab in 10 mL of water.
Omeprazole is a substituted benzimidazole that suppresses acid secretion by specific inhibition of hydrogen potassium/ATPase at the secretory surface of the parietal cell.
Pantoprazole is a substituted benzimidazole that suppresses acid secretion by specific inhibition of hydrogen potassium/ATPase at the secretory surface of the parietal cell.
Somatostatin analogues are synthetic analogues of somatostatin that inhibit growth (GH) secretion, thereby leading to a decrease in chloride secretion, sodium absorption, and decreased fluid losses. These agents are used to treat secretory diarrhea in Zollinger-Ellison syndrome.
Octreotide acts primarily on somatostatin receptor subtypes II and V. This agent inhibits growth hormone (GH) secretion and has a multitude of other endocrine and nonendocrine effects, including inhibition of glucagon, vasoactive intestinal peptide (VIP), and gastrointestinal (GI) peptides. Octreotide controls diarrhea in 80% of patients, but progressive increases in dosage may be necessary. In adults, Mozell et al reported success with 100 mcg subcutaneously (SC) 3 times/wk for 1-48 months.
Massaro SA, Emre SH. Metastatic Gastrinoma in a Pediatric Patient With Zollinger-Ellison Syndrome. J Pediatr Hematol Oncol. 2013 Feb 15. [Medline].
Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore). 2004 Jan. 83(1):43-83. [Medline].
Imamura M, Komoto I, Ota S. Changing treatment strategy for gastrinoma in patients with Zollinger-Ellison syndrome. World J Surg. 2006 Jan. 30(1):1-11. [Medline].
Passaro E, Howard TJ, Sawicki MP, et al. The origin of sporadic gastrinomas within the gastrinoma triangle: a theory. Arch Surg. 1998 Jan. 133(1):13-6; discussion 17. [Medline].
Debelenko LV, Emmert-Buck MR, Zhuang Z, et al. The multiple endocrine neoplasia type I gene locus is involved in the pathogenesis of type II gastric carcinoids. Gastroenterology. 1997 Sep. 113(3):773-81. [Medline].
Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med. 1999 Mar 18. 340(11):858-68. [Medline].
Riff BP, Leiman DA, Bennett B, Fraker DL, Metz DC. Weight Gain in Zollinger-Ellison Syndrome After Acid Suppression. Pancreas. 2015 Jul 8. [Medline].
Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med. 1999 Aug 26. 341(9):635-44. [Medline].
Nord KS, Joshi V, Hanna M, et al. Zollinger-Ellison syndrome associated with a renal gastrinoma in a child. J Pediatr Gastroenterol Nutr. 1986 Nov-Dec. 5(6):980-6. [Medline].
Morrow EH, Norton JA. Surgical management of Zollinger-Ellison syndrome; state of the art. Surg Clin North Am. 2009 Oct. 89(5):1091-103. [Medline].
Eire PF, Rodriguez Pereira C, Barca Rodriguez P, Varela Cives R. Uncommon case of gastrinoma in a child. Eur J Pediatr Surg. 1996 Jun. 6(3):173-4. [Medline].
Heikenen JB, Pohl JF, Werlin SL. Octreotide in pediatric patients. J Pediatr Gastroenterol Nutr. 2002 Nov. 35(5):600-9. [Medline].
Kim HU. Diagnostic and Treatment Approaches for Refractory Peptic Ulcers. Clin Endosc. 2015 Jul. 48 (4):285-90. [Medline].
Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore). 2006 Nov. 85(6):295-330. [Medline].
Berna MJ, Hoffmann KM, Long SH, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore). 2006 Nov. 85(6):331-64. [Medline].
Proye C, Malvaux P, Pattou F, et al. Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy. Surgery. 1998 Dec. 124(6):1134-43; discussion 1143-4. [Medline].
Norton JA, Melcher ML, Gibril F, Jensen RT. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery. 2004 Dec. 136(6):1267-74. [Medline].
Epelboym I, Mazeh H. Zollinger-Ellison syndrome: classical considerations and current controversies. Oncologist. 2014 Jan. 19 (1):44-50. [Medline].
Corleto VD, Annibale B, Gibril F, et al. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome?. Aliment Pharmacol Ther. 2001 Oct. 15(10):1555-61. [Medline].
Jensen RT. Gastrinomas: Advances in Diagnosis and Management. Neuroendocrinology. 2004. 80 Suppl 1:23-27. [Medline].
Kwekkeboom DJ, de Herder WW, van Eijck CH, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2010 Mar. 40(2):78-88. [Medline].
Citak EC, Taskinlar H, Arpaci RB, Apaydin FD, Gunay EC, Tanriverdi H, et al. Primary lymph node gastrinoma: a rare cause of abdominal pain in childhood. J Pediatr Hematol Oncol. 2013 Jul. 35(5):394-8. [Medline].
Mozell EJ, Cramer AJ, O'Dorisio TM, Woltering EA. Long-term efficacy of octreotide in the treatment of Zollinger-Ellison syndrome. Arch Surg. 1992 Sep. 127(9):1019-24; discussion 1024-6. [Medline].
Berna MJ, Annibale B, Marignani M, et al. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab. 2008 May. 93(5):1582-91. [Medline].
Ellison EC, Johnson JA. The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations. Curr Probl Surg. 2009 Jan. 46(1):13-106. [Medline].
Gibril F, Jensen RT. Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome. Curr Gastroenterol Rep. 2005 May. 7(2):114-21. [Medline].
Quatrini M, Castoldi L, Rossi G, et al. A follow-up study of patients with Zollinger-Ellison syndrome in the period 1966-2002: effects of surgical and medical treatments on long-term survival. J Clin Gastroenterol. 2005 May-Jun. 39(5):376-80. [Medline].